Maria Marvich

Array ( [id] => 19884177 [patent_doc_number] => 12269870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Antigen binding regions against fibronectin type III domains and methods of using the same [patent_app_type] => utility [patent_app_number] => 17/493032 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 32 [patent_no_of_words] => 21738 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563425 [patent_doc_number] => 20220127574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => Universal Killer T-Cell [patent_app_type] => utility [patent_app_number] => 17/483484 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444170 [patent_doc_number] => 20220064675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS [patent_app_type] => utility [patent_app_number] => 17/479577 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444170 [patent_doc_number] => 20220064675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS [patent_app_type] => utility [patent_app_number] => 17/479577 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428382 [patent_doc_number] => 20220056090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => AAV-EPO FOR TREATING COMPANION ANIMALS [patent_app_type] => utility [patent_app_number] => 17/472037 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428382 [patent_doc_number] => 20220056090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => AAV-EPO FOR TREATING COMPANION ANIMALS [patent_app_type] => utility [patent_app_number] => 17/472037 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314904 [patent_doc_number] => 20210403952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF [patent_app_type] => utility [patent_app_number] => 17/467425 [patent_app_country] => US [patent_app_date] => 2021-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444169 [patent_doc_number] => 20220064674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => CD62L specific lentiviral vector particle for targeted transduction of T cell subsets [patent_app_type] => utility [patent_app_number] => 17/465734 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704989 [patent_doc_number] => 20220204995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => NON-DISRUPTIVE GENE TARGETING [patent_app_type] => utility [patent_app_number] => 17/458044 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076714 [patent_doc_number] => 11946065 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB [patent_app_type] => utility [patent_app_number] => 17/387035 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 33 [patent_no_of_words] => 21637 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355467 [patent_doc_number] => 20220016263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => FABRY DISEASE GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/386063 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391731 [patent_doc_number] => 20230159949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => ENGINEERED MUSCLE TARGETING COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/614327 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -113 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503475 [patent_doc_number] => 20220096577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ONCOLYTIC ADENOVIRUS COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/371546 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503475 [patent_doc_number] => 20220096577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ONCOLYTIC ADENOVIRUS COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/371546 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185500 [patent_doc_number] => 20210332385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/369168 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185500 [patent_doc_number] => 20210332385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/369168 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185500 [patent_doc_number] => 20210332385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/369168 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537811 [patent_doc_number] => 20230242912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHODS AND COMPOSITIONS RELATED TO CATALYTIC ACTIVATION OF HUMAN ARGONAUTE-3 [patent_app_type] => utility [patent_app_number] => 18/011799 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17357127 [patent_doc_number] => 20220017923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => HELPER-DEPENDENT ADENOVIRAL GENE THERAPY DELIVERY AND EXPRESSION SYSTEM [patent_app_type] => utility [patent_app_number] => 17/358904 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17996684 [patent_doc_number] => 11497770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy [patent_app_type] => utility [patent_app_number] => 17/354624 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 38443 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354624 [rel_patent_id] =>[rel_patent_doc_number] =>)